Neoadjuvant chemotherapy in advanced ovarian cancer: what is the optimal number of cycles?

被引：0
|
作者：
Ltaief, Sarra Ben [1 ]
Bouhani, Malek [1 ]
Houissa, Iness [1 ]
Sakhri, Saida [1 ]
Bouaziz, Hanen [1 ]
Dhiab, Tarek Ben [1 ]
机构：
[1] Inst Salah Aziez Tunisia, Surg Oncol, Tunis Ville, Tunisia
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2024年 / 34卷 / SUPPL_3期
关键词：
D O I：
10.1136/ijgc-2024-IGCS.344
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EV225
引用
收藏
页码：A200 / A200
页数：1
相关论文
共 50 条
  • [31] The role of neoadjuvant chemotherapy in advanced ovarian cancer: The right treatment to the right patient - Ensuring optimal outcomes in advanced ovarian cancer
    Armbrust, Robert
    Fotopoulou, Christina
    Sehouli, Jalid
    BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2024, 131 (11) : 1573 - 1574
  • [32] Neoadjuvant chemotherapy with six cycles of carboplatin and paclitaxel in advanced ovarian cancer patients not candidates for optimal primary surgery: Safety and effectivenes
    Miranda, Vanessa Costa
    de Sousa Fede, Angelo Bezerra
    Dos Anjos, Carlos Henrique
    da Silva, Juliana Ribeiro
    Sanchez, Fernando Barbosa
    da Silva Bessa, Lyvia Rodrigues
    Carvalho, Jesus Paula
    Abdo Filho, Elias
    Freitas, Daniela
    Borges de Barros, Laryssa Almeida
    Severino da Silva, Samantha Cabral
    Estevez-Diz, Maria Del Pilar
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [33] Impact of neoadjuvant chemotherapy cycles prior to interval surgery in patients with advanced epithelial ovarian cancer
    Colombo, P. E.
    Labaki, M.
    Fabbro, M.
    Bertrand, M.
    Mourregot, A.
    Gutowski, M.
    Saint-Aubert, B.
    Quenet, F.
    Rouanet, P.
    Mollevi, C.
    GYNECOLOGIC ONCOLOGY, 2014, 135 (02) : 223 - 230
  • [34] Impact of neoadjuvant chemotherapy and postoperative adjuvant chemotherapy cycles on survival of patients with advanced-stage ovarian cancer
    Chung, Young Shin
    Kim, Yun-Ji
    Lee, Inha
    Lee, Jung-Yun
    Nam, Eun Ji
    Kim, Sunghoon
    Kim, Sang Wun
    Kim, Young Tae
    PLOS ONE, 2017, 12 (09):
  • [35] Is Optimal Cytoreduction Post Neoadjuvant Chemotherapy the Only Prognostic Factor in Advanced Ovarian Cancer?
    Dhiman, Pravesh
    Bapsy, P. P.
    Patil, C. N.
    Raghupathi, Renu
    SOUTH ASIAN JOURNAL OF CANCER, 2022, 11 (03) : 207 - 212
  • [36] Intraperitoneal chemotherapy following neoadjuvant chemotherapy and optimal interval tumor reductive surgery for advanced ovarian cancer
    Bixel, K.
    Vetter, M.
    Davidson, B.
    Berchuck, A.
    Cohn, D.
    Copeland, L.
    Fowler, J. M.
    Havrilesky, L.
    Lee, P. S.
    O'Malley, D. M.
    Salani, R.
    Valea, F.
    Secord, A. Alvarez
    Backes, F.
    GYNECOLOGIC ONCOLOGY, 2020, 156 (03) : 530 - 534
  • [37] IMPACT OF THE NUMBER OF CYCLES OF NEOADJUVANT CHEMOTHERAPY BEFORE INTERVAL DEBULKING SURGERY ON SURVIVAL IN ADVANCED STAGES OVARIAN CANCER : A MULTICENTRIC RETROSPECTIVE STUDY
    Akladios, C.
    Shrot-Sanyan, S.
    Decok, L.
    Petit, T.
    Robstock, L.
    Baldauf, J.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2015, 25 (09) : 1270 - 1271
  • [38] Optimizing the number of cycles of neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma: A propensity-score matching analysis
    Marchetti, C.
    Rosati, A.
    De Felice, F.
    Boccia, S. M.
    Vertechy, L.
    Pavone, M.
    Palluzzi, E.
    Scambia, G.
    Fagotti, A.
    GYNECOLOGIC ONCOLOGY, 2021, 163 (01) : 29 - 35
  • [39] OPTIMIZING THE NUMBER OF CYCLES OF NEOADJUVANT CHEMOTHERAPY IN ADVANCED EPITHELIAL OVARIAN CARCINOMA: A PROPENSITY-SCORE MATCHING ANALYSIS
    Rosati, A.
    Marchetti, C.
    De Felice, F.
    Boccia, S.
    Vertechy, L.
    Pavone, M.
    Palluzzi, E.
    Scambia, G.
    Fagotti, A.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 : A20 - A20
  • [40] Neoadjuvant chemotherapy in advanced stage epithelial ovarian cancer
    Kartsiounis, Christos
    Mitsakis, Ioannis
    Boutis, Anastasios
    Triantafillidis, Efstathios
    Evangelinos, Dimitrios
    Andreadis, Charalambos
    Kellartzis, Argirios
    ANNALS OF ONCOLOGY, 2006, 17 : 175 - 175
12345